Related Experiment Videos
[Calcium channel blockers in heart failure]
T Hole1, K Dickstein, T Gundersen
1Medisinsk avdeling, Sentralsjukehuset i Møre og Romsdal, Alesund.
Summary
Calcium channel blockers are not recommended for patients with heart failure due to impaired calcium delivery and sympathetic reflexes. Amlodipine or felodipine may be considered for angina when other treatments fail.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Heart failure patients exhibit impaired calcium handling and attenuated sympathetic reflexes.
- Systolic left ventricular dysfunction complicates the use of calcium channel blockers.
Purpose:
- To evaluate the role and safety of calcium channel blockers in patients with heart failure and coronary artery disease.
- To identify potential therapeutic alternatives for angina in specific cardiac conditions.
Summary:
- Calcium channel blockers (CCBs) are generally contraindicated in heart failure with systolic left ventricular dysfunction.
- These agents can exacerbate the condition due to underlying myocardial calcium delivery defects and altered sympathetic responses.
- For patients with coronary artery disease experiencing angina unresponsive to beta-blockers or nitrates, specific CCBs like amlodipine or felodipine may be cautiously considered.
Impact:
- This guidance aims to prevent adverse events and optimize treatment strategies for patients with complex cardiovascular conditions.
- Highlights the need for individualized treatment approaches in managing heart failure and angina concurrently.